Altimmune, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALT Nasdaq 2836 altimmune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Altimmune, Inc.

Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026 - Oct 19th, 2026 6:00 am
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care? - Oct 7th, 2026 7:02 am
Altimmune Details Pemvidutide’s Path Toward a Liver-Disease Franchise - Oct 1st, 2026 5:02 am
Altimmune to Participate in Stifel Cardiometabolic Forum - Sep 23rd, 2026 6:00 am
VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’ - Sep 21st, 2026 11:29 pm
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report? - Sep 11th, 2026 9:30 am
Altimmune’s (ALT) Three Liver Trials Move Forward At Once - Sep 7th, 2026 8:27 pm
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference - Sep 3rd, 2026 6:00 am
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger? - Aug 19th, 2026 8:55 am
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus - Aug 19th, 2026 8:54 am
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus - Aug 14th, 2026 8:14 am
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus - Aug 13th, 2026 10:14 am
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ... - Aug 12th, 2026 5:03 pm
Altimmune Q2 Earnings Call Highlights - Aug 12th, 2026 8:05 am
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA - Aug 12th, 2026 6:54 am
Altimmune, Inc. Q2 2026 Earnings Call Summary - Aug 12th, 2026 6:30 am
Altimmune Announces Second Quarter 2026 Financial Results and Business Update - Aug 12th, 2026 5:30 am
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema - Aug 11th, 2026 9:15 am
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised - Aug 7th, 2026 9:15 am
Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates - Aug 6th, 2026 12:24 pm